By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Gulf PressGulf Press
  • Home
  • Gulf News
    • Saudi Arabia
    • UAE24/7
    • Kuwait
    • Qatar
    • Bahrain
    • Oman
  • World
  • Business
    • Market DataLive
    • Finance
    • Economy
    • Energy
    • Crypto
    • ForexHot
    • Tech
  • Sports
  • Lifestyle
  • Videos
Search
Countries
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Bahrain
  • Oman
More Topics
  • Technology
  • Health
  • Entertainment
  • Crypto
  • Forex
  • Stocks
Site Links
  • Business Hub
  • Trending
  • Weather
  • Customize Interests
  • Bookmarks
  • Newsletter
  • Terms
  • Press Release
  • Advertise
  • Contact
© 2023 Gulf Press. All Rights Reserved.
Reading: J&J exceeds Wall Street expectations with robust drug sales, earns $22.4B in revenue in Q2 – News
Share
Notification Show More
Recent Saved
Workers in Bucharest face challenges as temperatures rise
World
Dress code guidelines for the Qatari government sector during office hours
Qatar
Court rules in favor of worker after company dismisses him for salary deductions over 6 years, awarding BD 27,000.
Bahrain
UAE to See Almost 30,000 New Millionaires in 5 Years
UAE
Proposed New Labor Law in Bahrain Targets Increasing Job Opportunities
Bahrain
Latest News
UAE Ranks Among Top Rugby Markets on TOD as British & Irish Lions Tour Kicks Off
Sports
Darven: A New Leap in AI-Powered Legal Technology Launching from the UAE to the World
Tech
Beat the Heat This Summer with a Chill Out on Dubai Marina
World
Historic Italian City of Assisi to Host International Exhibition “Jordan: Dawn of Christianity”
World
Jordan to Host Iraq in the Final Round of the Asian World Cup Qualifiers After Securing Historic Spot
Sports
Aa
Gulf PressGulf Press
Aa
  • Gulf News
  • World
  • Business
  • Entertainment
  • Lifestyle
  • Sports
  • Videos
Search
  • Home
    • Videos
    • Business Hub
    • Trending
  • Gulf
    • Saudi Arabia
    • UAE
    • Kuwait
    • Qatar
    • Bahrain
    • Oman
  • Business
    • Market Data
    • Crypto
    • Economy
    • Energy
    • Finance
    • Forex
    • Tech
  • More News
    • World
    • Lifestyle
    • Entertainment
    • Sports
Have an existing account? Sign In
Follow US
  • Terms
  • Press Release
  • Advertise
  • Contact
© 2023 Gulf Press. All Rights Reserved.
Gulf Press > Business > J&J exceeds Wall Street expectations with robust drug sales, earns $22.4B in revenue in Q2 – News
Business

J&J exceeds Wall Street expectations with robust drug sales, earns $22.4B in revenue in Q2 – News

News Room
Last updated: 2024/07/18 at 1:11 PM
News Room
Share
3 Min Read
SHARE

Johnson & Johnson, a well-known drug and device maker, surpassed estimates for second-quarter profit and revenue, fueled by strong sales of its drugs, specifically cancer treatment Darzalex and psoriasis drug Stelara. Revenue of $22.4 billion exceeded the consensus estimate, while adjusted earnings of $2.82 per share outperformed analysts’ expectations. Stelara sales increased by 3.1 percent to $2.89 billion, while Darzalex sales rose by 18.4 percent to $2.88 billion. The company now anticipates total sales of $89.2 billion to $89.6 billion for 2024, up from its prior forecast.
J&J also revised its annual per-share forecast to a range of $10 to $10.10 from $10.60 to $10.75, citing improved performance and higher costs related to acquisitions. The company has been active in the acquisition space, including the purchase of cardiac medical device company Shockwave for $13 billion and experimental skin disorder drugs in two separate transactions totaling $2.1 billion. While medical technology business sales increased by 2.2 percent, they fell short of analysts’ estimates.
Analysts predict Stelara sales to exceed $10 billion this year, but they may drop to approximately $7 billion in 2025 due to upcoming competition from similar drugs. J&J’s CFO, Joe Wolk, expressed confidence in securing favorable US insurance coverage for Stelara in 2025 through future contracts. Despite facing biosimilar competition in the following year, the company expects growth in its pharmaceutical business. Darzalex, a blood cancer therapy, is projected to generate over $11 billion in sales for J&J this year.
Sales of Imbruvica, another cancer drug by J&J, reached $770 million, surpassing analyst expectations. Carvykti, the company’s cancer cell therapy, saw sales of $186 million, a 60 percent increase from the previous year, but slightly below analysts’ predictions. The limited Carvykti supply has been attributed to production constraints, prompting J&J to enhance capacity at its facilities in New Jersey and Belgium.
In conclusion, Johnson & Johnson’s strong performance in the second quarter was largely driven by the success of its drug portfolio, particularly Darzalex and Stelara. While the company exceeded revenue and profit estimates, it faces challenges in managing biosimilar competition for certain drugs in the future. With strategic acquisitions and efforts to enhance production capacity, J&J remains optimistic about its pharmaceutical business growth despite market uncertainties. Investors will be closely watching how the company navigates upcoming challenges and maintains its competitive edge in the healthcare industry.

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
I have read and agree to the terms & conditions
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
News Room July 18, 2024
Share this Article
Facebook Twitter Copy Link Print
Previous Article Saudi and Kuwaiti military leaders discuss cooperation
Next Article The process of becoming an Olympian: Dubai-based Pakistani swimmer shares insights
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected

235.3k Followers Like
69.1k Followers Follow
56.4k Followers Follow
136k Subscribers Subscribe
- Advertisement -
Ad imageAd image

Latest News

UAE Ranks Among Top Rugby Markets on TOD as British & Irish Lions Tour Kicks Off
Sports July 6, 2025
Darven: A New Leap in AI-Powered Legal Technology Launching from the UAE to the World
Tech July 1, 2025
Beat the Heat This Summer with a Chill Out on Dubai Marina
World July 1, 2025
Historic Italian City of Assisi to Host International Exhibition “Jordan: Dawn of Christianity”
World June 28, 2025

You Might also Like

Tech

Darven: A New Leap in AI-Powered Legal Technology Launching from the UAE to the World

July 1, 2025
Crypto

Bitget Celebrates Bitcoin Pizza Day by Distributing Over 5000 Pizzas in Over 20 Cities Worldwide

May 22, 2025
BusinessCrypto

Bitget Protection Fund Maintains Strength with $561 Million Average Value in April 2025

May 20, 2025
BusinessGulfUAE

Muhammad Umair Saeed: The Billionaire Tech Architect Powering AI, Drones, Blockchain & Cybersecurity from Dubai to the World

May 10, 2025
BusinessCrypto

RWA project FEXSE tokenises $600,000 Jacob & Co. luxury watch on the blockchain

April 14, 2025
Business

NTT DATA Business Solutions Expands Presence in UAE with Stronger Regional Leadership

March 28, 2025

Sustainable Moving Services: How Dubai’s Moving Companies Are Going Green

February 20, 2025
Tech

CNTXT and Oracle Strengthen AI Collaboration to Drive Innovation

February 14, 2025
//

Gulf Press is your one-stop website for the latest news and updates about Arabian Gulf and the world, follow us now to get the news that matters to you.

Quick Link

  • Privacy Policy
  • Terms of ue
  • Advertise
  • Contact

How Topics

  • Gulf News
  • International
  • Business
  • Lifestyle

Sign Up for Our Newsletter

Subscribe to our newsletter to get our latest news instantly!

I have read and agree to the terms & conditions
Gulf PressGulf Press
Follow US

© 2023 Gulf Press. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc..

I have read and agree to the terms & conditions
Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?